Abpro (ABP) Competitors $0.28 +0.01 (+5.42%) As of 04/11/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsOwnershipSEC FilingsTrendsBuy This Stock ABP vs. UNCY, IOBT, PYXS, ANRO, STRO, MGX, JSPR, IKNA, BDRX, and MDCXShould you be buying Abpro stock or one of its competitors? The main competitors of Abpro include Unicycive Therapeutics (UNCY), IO Biotech (IOBT), Pyxis Oncology (PYXS), Alto Neuroscience (ANRO), Sutro Biopharma (STRO), Metagenomi (MGX), Jasper Therapeutics (JSPR), Ikena Oncology (IKNA), Biodexa Pharmaceuticals (BDRX), and Medicus Pharma (MDCX). These companies are all part of the "pharmaceutical products" industry. Abpro vs. Unicycive Therapeutics IO Biotech Pyxis Oncology Alto Neuroscience Sutro Biopharma Metagenomi Jasper Therapeutics Ikena Oncology Biodexa Pharmaceuticals Medicus Pharma Abpro (NASDAQ:ABP) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, analyst recommendations, media sentiment, profitability and earnings. Which has stronger earnings & valuation, ABP or UNCY? Abpro has higher earnings, but lower revenue than Unicycive Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbpro$122K117.22N/AN/AN/AUnicycive Therapeutics$680K96.40-$30.54M-$1.07-0.51 Do institutionals and insiders believe in ABP or UNCY? 23.3% of Abpro shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 19.8% of Abpro shares are held by insiders. Comparatively, 24.1% of Unicycive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media refer more to ABP or UNCY? In the previous week, Unicycive Therapeutics had 3 more articles in the media than Abpro. MarketBeat recorded 5 mentions for Unicycive Therapeutics and 2 mentions for Abpro. Abpro's average media sentiment score of 0.93 beat Unicycive Therapeutics' score of 0.68 indicating that Abpro is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abpro 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Unicycive Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in ABP or UNCY? Unicycive Therapeutics received 33 more outperform votes than Abpro when rated by MarketBeat users. However, 100.00% of users gave Abpro an outperform vote while only 77.27% of users gave Unicycive Therapeutics an outperform vote. CompanyUnderperformOutperformAbproOutperform Votes1100.00% Underperform VotesNo VotesUnicycive TherapeuticsOutperform Votes3477.27% Underperform Votes1022.73% Is ABP or UNCY more profitable? Company Net Margins Return on Equity Return on Assets AbproN/A N/A N/A Unicycive Therapeutics N/A N/A -29.88% Do analysts rate ABP or UNCY? Abpro presently has a consensus price target of $4.00, indicating a potential upside of 1,349.28%. Unicycive Therapeutics has a consensus price target of $5.25, indicating a potential upside of 858.73%. Given Abpro's higher possible upside, analysts clearly believe Abpro is more favorable than Unicycive Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Unicycive Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Which has more risk & volatility, ABP or UNCY? Abpro has a beta of -0.07, meaning that its stock price is 107% less volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500. SummaryUnicycive Therapeutics beats Abpro on 9 of the 14 factors compared between the two stocks. Remove Ads Get Abpro News Delivered to You Automatically Sign up to receive the latest news and ratings for ABP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABP vs. The Competition Export to ExcelMetricAbproHolding Offices IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.30M$445.34M$5.28B$7.55BDividend YieldN/A8.23%5.11%4.33%P/E RatioN/A2.3621.5517.71Price / Sales117.2253.82364.7493.58Price / CashN/A69.0138.1534.64Price / BookN/A3.496.293.90Net IncomeN/A$35.22M$3.20B$247.45M7 Day Performance-9.57%-0.24%2.05%2.34%1 Month Performance-42.38%-2.42%-10.43%-8.64%1 Year PerformanceN/A17.09%5.25%-3.88% Abpro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABPAbproN/A$0.28+5.4%$4.00+1,349.3%N/A$14.30M$122,000.000.0015Gap UpUNCYUnicycive Therapeutics2.6121 of 5 stars$0.47+2.0%$5.25+1,016.8%-55.1%$56.27M$680,000.00-0.489Analyst ForecastIOBTIO Biotech2.8556 of 5 stars$0.83-8.5%$9.33+1,021.5%-44.7%$54.83MN/A-0.6130Gap UpPYXSPyxis Oncology1.5017 of 5 stars$0.88-8.3%$9.20+948.7%-80.5%$54.03M$16.15M-0.8560Positive NewsGap UpANROAlto Neuroscience1.4809 of 5 stars$2.00-11.7%$15.40+671.9%-85.2%$54.01MN/A-0.79N/AGap UpSTROSutro Biopharma4.2675 of 5 stars$0.64-11.8%$6.63+943.1%-85.4%$52.37M$62.04M-0.39240Positive NewsGap UpMGXMetagenomi2.0168 of 5 stars$1.40-2.1%$13.00+828.6%-83.5%$52.34M$52.30M-0.53236Gap DownJSPRJasper Therapeutics2.5745 of 5 stars$3.47-2.8%$62.50+1,701.2%-85.0%$52.13MN/A-0.7320News CoveragePositive NewsGap UpIKNAIkena Oncology2.5695 of 5 stars$1.08+4.9%$3.00+177.8%-17.3%$52.12M$659,000.00-0.8870Positive NewsGap UpBDRXBiodexa Pharmaceuticals0.601 of 5 stars$1.41-14.5%N/AN/A$51.53M$83,000.000.0020MDCXMedicus PharmaN/A$3.63-5.5%$10.00+175.5%N/A$51.51MN/A0.00N/AAnalyst RevisionNews Coverage Remove Ads Related Companies and Tools Related Companies UNCY Alternatives IOBT Alternatives PYXS Alternatives ANRO Alternatives STRO Alternatives MGX Alternatives JSPR Alternatives IKNA Alternatives BDRX Alternatives MDCX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABP) was last updated on 4/14/2025 by MarketBeat.com Staff From Our PartnersO-Farming Income TrickHave you heard of this unusual way to collect monthly income from the oil markets? (starting with under $10...Buildofarm | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredThe biggest story CNBC isn't talking about (yet)This Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...Stansberry Research | SponsoredThe Secret Las Vegas Economic Summit (shocking)A secret Wall Street meeting in Las Vegas just took place — and one economist says it eerily echoes 2008. Here...Banyan Hill Publishing | SponsoredPlease — Don’t PanicMarkets are in turmoil — but TradeSmith CEO Keith Kaplan says panic isn’t the answer. Instead, he believes thi...InvestorPlace | SponsoredTrump’s betrayal exposed Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abpro Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Abpro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ABP Stock Free ABP Stock Alerts